Gout and Hyperuricaemia Treatment
Gout and Hyperuricaemia Treatment
Gout is treated on two tracks that are easy to confuse and expensive to confuse. The first is the attack: an inflammatory event that is stopped with anti-inflammatory medicine and that resolves on its own in any case. The second is the level: urate held below saturation long enough for existing crystals to dissolve and new ones not to form. This page takes them in order, then turns to the kidney and stone side, the dietary work, the integrated medicine pathway, and what treatment asks of a person over years rather than weeks.
Settling the attack
An attack is inflammation, and it is treated as inflammation. Three families of medicine do this, they work about equally well when given early enough, and the choice between them is made from the patient rather than from the drug.
| Option | How it is used | Who it suits, and who it does not |
|---|---|---|
| Non-steroidal anti-inflammatory drugs | At full anti-inflammatory dose, started as early as possible and tapered as the attack settles | The default for a young, otherwise well patient. Avoided or used with care where kidney function is reduced, where there is a history of ulcer or bleeding, or where heart failure or anticoagulation complicates the picture |
| Colchicine | Low dose, given early; most effective within the first day and much less so later | Useful where anti-inflammatories are unsuitable. Dose adjusted for kidney function, and the interactions — particularly with some statins and antibiotics — checked before it is prescribed |
| Glucocorticoids | Orally for a few days, or injected into the joint where a single joint is involved and infection has been excluded | Suited to patients with reduced kidney function, and to those in whom the other two are contraindicated. A short course, not a maintenance treatment |
Two things about the attacking side are worth stating plainly because they cause the most confusion. The first is that urate-lowering medicine does not treat an attack. Allopurinol started during a flare does nothing for the pain and can prolong it; the attack is treated separately, and the long-term medicine is started once the joint is quiet. The second is that rest, elevation and ice help, while the treatments patients often reach for first — rubbing the joint, or continuing to walk on it — do not.
And one caution that belongs here rather than in a footnote: any hot joint treated as gout when it is actually infected loses days that matter. Where fever, a prosthetic joint or immunosuppression is present, the joint is aspirated before anti-inflammatory treatment is assumed to be the answer.
Lowering the urate, and holding it there
This is the part of treatment that changes the disease rather than the episode, and it has a logic that is worth understanding because it explains the otherwise discouraging first few months.
The aim is to hold serum urate below the concentration at which crystals form, and below it continuously. Above that line, crystals persist and can grow; below it, they dissolve, slowly. Because crystals dissolve slowly, the attacks can continue for a while after the level has reached target — this is the period during which patients most often conclude the medicine is not working, and it is exactly the period during which it is working.
Two families of medicine do this, by opposite routes. Xanthine oxidase inhibitors — allopurinol and febuxostat — reduce production. Uricosuric agents increase the kidney's excretion of urate, and are used where the problem is clearance and kidney function allows. The choice is made from the mechanism identified in the assessment, from kidney function, and from tolerance.
The method matters more than the choice. The medicine is started low and titrated: dose increased at intervals with the level measured each time, until the target is reached, then held. Starting at what will eventually be the maintenance dose is the commonest cause of the early flares that make patients abandon treatment, and it is entirely avoidable.
So is the second commonest cause. Beginning urate-lowering therapy mobilises crystals and can provoke attacks, which is why the first months are covered by prophylaxis — a low dose of colchicine or an anti-inflammatory continued for several months. Patients are told this in advance, because a medicine that prevents attacks in the long run can appear to cause one in the short run, and the difference is explained rather than discovered.
The kidney side: stones, urate nephropathy and the medicines review
Gout and the kidney are entangled in both directions, and this is the part of treatment that belongs to the same team rather than to two separate clinics.
Kidney stones. Urate stones form where the urine is acidic and the urate load is high, and they are radiolucent — invisible on a plain X-ray, which is why they are missed. They cause colic, they can obstruct, and they are managed by increasing urine volume, alkalinising the urine where indicated and lowering the urate load. A stone that has been passed should be analysed; composition changes the prevention.
Urate nephropathy. Urate can crystallise within the kidney tissue, producing a chronic interstitial nephropathy that is generally silent until filtration has already fallen. It is one of the reasons a patient with gout should have kidney function measured rather than assumed, and one of the reasons urate lowering is not only about joints.
The medicines review. This is the most productive step in the whole plan and the one most often skipped. Thiazide and loop diuretics, low-dose aspirin, ciclosporin, pyrazinamide and ethambutol all raise urate, and several are prescribed for conditions that gout travels with — hypertension and heart failure among them. Where the indication allows a substitute, one change can remove the need for another medicine. Where it does not, the urate-lowering dose simply has to be higher, and the reason should be written down rather than discovered at each visit.
Protecting filtration. Where kidney function is already reduced, doses are adjusted to it, anti-inflammatory choices are narrowed, and the level is tracked alongside filtration rather than on its own. Our department runs the urate work and the kidney work in the same place, which is the practical reason this cluster sits where it does.
What food and drink actually do
Dietary advice for gout has a poor reputation because it has been oversold for a century. The honest version is more useful: several things raise the level measurably, several do not, and none of them replaces the medicine.
| Item | What it does to urate | How much it asks |
|---|---|---|
| Fructose-sweetened drinks | Raises it, through a mechanism that increases purine turnover | The clearest dietary effect in the list, and the easiest to remove |
| Alcohol, particularly beer and spirits | Raises it: beer carries purine as well as alcohol, and alcohol reduces excretion | Reducing intake lowers both the level and the frequency of attacks |
| Red meat, offal and some seafood | Raises it modestly, in proportion to purine content | Portion and frequency matter more than total exclusion |
| Weight gain, and crash dieting | Both raise it — the first through clearance, the second through ketosis competing with urate excretion | Steady loss helps; rapid loss can trigger an attack, which is worth warning about in advance |
| Water | Helps the kidney clear urate and reduces stone risk | The least glamorous item in the list and one of the more effective |
One myth deserves closing. Cherry products, coffee, vitamin C and various supplements have been studied with modest and inconsistent effects; none of them is a treatment, and none of them should be taken instead of a medicine that reaches the target. Anything taken for gout — including anything bought without a prescription — belongs on the list the treating team sees, because "natural" and "safe with your kidney function" are not the same claim.
The integrated Chinese and Western medicine pathway
Our traditional Chinese medicine department runs a dedicated gout clinic, and patients who want a combined approach are managed across both departments rather than having to choose between them.
The framing matters. Urate lowering, attack treatment and kidney protection remain the conventional side of the plan, and the number that has to come down is still measured in the same units. Chinese medicine is added to that plan — an individualised regimen adjusted over time — rather than substituted for it. Where a patient asks specifically about Chinese medicine, the answer is that it is an addition with its own follow-up, not an alternative that allows the urate target to be ignored.
What it is used for in practice is the part patients ask about: the interval between attacks, the residual discomfort that outlasts the visible inflammation, and the digestive and metabolic picture that travels with the condition. It is also where the dietary and constitution work sits, in a structure with regular review rather than a prescription handed over once.
The practical arrangement is deliberately simple. Both sides see the same urate results, the same kidney function tests and the same medicines list, and the plan is written down in one document so that the two do not contradict each other. Where a patient's local team is continuing care after they go home, that document is what they receive.
What treatment asks of a person
Taken together, treatment for gout is less a course than a routine: a level measured at intervals, a dose that moves with it, prophylaxis for the first months, and a medicines list reviewed once properly rather than renewed indefinitely.
The part patients control, and the part that matters more than most realise, sits in three places. Taking the urate-lowering medicine every day whether or not the joint hurts, because its work happens between attacks and not during them. Not stopping it during an attack, since stopping and restarting produces the flares that make the treatment look like the problem. And keeping the measurements, because the target is reached by titration and cannot be titrated without the numbers.
What treatment does not ask is that a person stop eating and drinking normally. The dietary changes that matter are specific and few, alcohol and fructose are the largest of them, and none of them is a prohibition. What it does ask is patience at the beginning: the level comes down in weeks, the attacks stop coming over months, and the tophi shrink over years. That sequence is worth stating at the start, because it is the difference between a person who stays on treatment and one who abandons it in month two.